PCSK9
Showing 1 - 25 of 352
Hemodialysis Access Failure Trial in Shanghai (pcsk9 inhibitor)
Recruiting
- Hemodialysis Access Failure
- pcsk9 inhibitor
-
Shanghai, Pudong, ChinaYuanyuan Xie
Sep 10, 2023
Abdominal Aortic Aneurysm Trial (Evolocumab, Placebo)
Not yet recruiting
- Abdominal Aortic Aneurysm
- Evolocumab
- Placebo
- (no location specified)
Oct 12, 2023
Stroke, Acute Ischemic, PCSK9 Inhibitor Trial in Seoul (Alirocumab)
Not yet recruiting
- Stroke, Acute Ischemic
- PCSK9 Inhibitor
-
Seoul, Korea, Republic ofAsan Medical Center
Oct 9, 2023
Acute Metabolic Effects of Evolocumab and Atorvastatin Trial (Evolocumab)
Not yet recruiting
- Acute Metabolic Effects of Evolocumab and Atorvastatin
- (no location specified)
Nov 16, 2023
PCSK9 Polymorphism and Risk of Cardiac Rupture
Recruiting
- Post-Infarction Heart Rupture
- Gene Polymorphism
- Genetic analysis for PCSK9 polymorphisms
-
Varese, ItalyMatteo Matteucci
Aug 15, 2022
Immunomodulatory Effects of PCSK9 Inhibition
Not yet recruiting
- Atherosclerotic Cardiovascular Disease
- +3 more
- Contrast-enhanced CCTA
- 99mTc-tilmanocept SPECT/CT scanning
-
Boston, MassachusettsMassachusetts General Hospital
Jan 30, 2023
Dyslipidemias, Hyperlipidemias, Liver Transplant Disorder Trial in Moscow (Pitavastatin, PCSK9 inhibitor)
Recruiting
- Dyslipidemias
- +5 more
- Pitavastatin
- PCSK9 inhibitor
-
Moscow, Russian FederationNational Medical Research Centre for Therapy and Preventive Medi
Sep 8, 2022
Early PCSK9 Inhibitor on Ventricular Remodling Trial in Shanghai (PCSK9 inhibitor (Alirocumab)plus standard medications,
Recruiting
- Early PCSK9 Inhibitor on Ventricular Remodling
- PCSK9 inhibitor (Alirocumab)plus standard medications
- standard medications
-
Shanghai, Shanghai, China
- +1 more
May 23, 2022
Adverse Effect of Cardiovascular Medications (Diagnosis) Trial in Zibo (Evolocumab combined with statins, Statin)
Recruiting
- Adverse Effect of Cardiovascular Medications (Diagnosis)
- Evolocumab combined with statins
- Statin
-
Zibo, Shandong, ChinaZibo Central Hospital
Mar 24, 2023
NSCLC (NSCLC) Trial (Alirocumab and Cemiplimab)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- Alirocumab and Cemiplimab
- (no location specified)
Jan 31, 2023
Sars-CoV-2 Infection Trial in Bydgoszcz (Evolocumab, Saline solution)
Completed
- Sars-CoV-2 Infection
- Evolocumab
- Saline solution
-
Bydgoszcz, PolandAntoni Jurasz University Hospital No. 1
Dec 14, 2022
Lipid Metabolism, Cardiovascular Diseases Trial in Shenzhen (PCSK9 inhibitor)
Recruiting
- Lipid Metabolism
- Cardiovascular Diseases
- PCSK9 inhibitor
-
Shenzhen, Guangdong, ChinaTangzhiming Li
May 4, 2022
Vasculopathy Trial in Stanford (alirocumab, )
Enrolling by invitation
- Vasculopathy
- alirocumab
- placebo
-
Stanford, CaliforniaStanford University
May 22, 2022
Cognitive Function in Patients Treated With PCSK9 Inhibitors
Completed
- Cognitive Function
- +2 more
- PCSK9 inhibitor
-
Cee, A Coruña, Spain
- +11 more
Jan 13, 2023
Acute Myocardial Infarction Trial in Shanghai (alirocumab, conventional treatment)
Recruiting
- Acute Myocardial Infarction
- alirocumab
- conventional treatment
-
Shanghai, Shanghai, China
- +3 more
Oct 31, 2022
Arteriosclerosis, Hypercholesterolaemia Trial (MK-0616, Placebo)
Not yet recruiting
- Arteriosclerosis
- Hypercholesterolaemia
- MK-0616
- Placebo
- (no location specified)
Aug 17, 2023
Intracranial Atherosclerosis, Acute Ischemic Stroke, ICAS - Intracranial Atherosclerosis Trial in Chiayi City (Alirocumab)
Recruiting
- Intracranial Atherosclerosis
- +2 more
-
Chiayi City, TaiwanYenchu Huang
Nov 29, 2022
Acute Coronary Syndrome, Hyperlipidemias, Percutaneous Coronary Intervention Trial in Nanjing (Placebo plus high-intensity
Not yet recruiting
- Acute Coronary Syndrome
- +3 more
- Placebo plus high-intensity statin
- PCSK 9 Inhibitor plus high-intensity statin
-
Nanjing, Jiangsu, ChinaNanjing First Hospital
Aug 1, 2022
Acute Coronary Syndrome Trial in Nanjing (Statin, PCSK9 inhibitor)
Not yet recruiting
- Acute Coronary Syndrome
- Statin
- PCSK9 inhibitor
-
Nanjing, Jiangsu, ChinaFirst Affiliated Hospital of Nanjing Medical University
Mar 17, 2022
Hypercholesterolemia, Familial Hypercholesterolemia Trial (MK-0616, Placebo)
Not yet recruiting
- Hypercholesterolemia
- Familial Hypercholesterolemia
- MK-0616
- Placebo
- (no location specified)
Jul 10, 2023